AbbVie Inc. (ABBV)
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.
How Much Dividend Income Can You Buy With $250,000?
A $250,000 rollover sounds like a clean starting point until you realize yield alone is not the whole story, and only one name on this roster actually clears the current Treasury rate.
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie
ADARx Pharmaceuticals is pursuing an IPO to fund its ambitious RNA-targeted therapy pipeline, targeting serious hepatic and non-hepatic diseases. ADRX's lead candidate, Onvuzosiran for hereditary angioedema, is in Phase 3 with topline data expected by end of 2027 and potential NDA in 2028. A substantial collaboration with AbbVie provided $335 million in upfront cash, $385 million in option payments, and up to $7.45 billion in milestones, plus royalties, supporting robust funding and validation.
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference
AbbVie NYSE: ABBV executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit its long-term strategy.
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, AbbVie (ABBV) closed at $248.78, indicating a -2.99% shift from the previous trading day.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
AbbVie's Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)
AbbVie remains a 'Buy', supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. The recent $11B Apogee Therapeutics acquisition enhances ABBV's pipeline in immunology, oncology, neuroscience, and aesthetics, with only modest near-term EPS dilution. Q2 results beat expectations, driven by Skyrizi and Rinvoq, while technicals and momentum favor continued upside toward a $292 price target.
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.
AbbVie's blood cancer drug meets late-stage trial goals
AbbVie said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
